Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
Open accessThe DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index; none of the 86 sources its claims cite is checked for support yet.
Abstract
At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence.
Overview
CoChat Summary
## TL;DR
This review argues that poor medication adherence in type 2 diabetes is common, often affecting at least half of patients, and is tied to worse glycemic control, higher costs, and higher mortality. It highlights two broad modifiable drivers: treatment burden and patients’ treatment-related beliefs.
## Key findings
- Reported poor medication adherence in T2D ranged from 38% to 93% across studies, largely because definitions and methods varied; using MPR ≥80%, adherence was 47.3% for dipeptidyl peptidase-4 inhibitors, 41.2% for sulfonylureas, and 36.7% for thiazolidinediones in a 238,000-patient MarketScan analysis.
- Poor adherence was associated with worse outcomes: among >11,000 veterans, MPR <80% was significantly associated with poor glycemic control (HbA1c >8%, P<0.001); in 1,198 survey respondents, each 1-point drop in self-reported adherence was linked to a 0.21% increase in HbA1c and increases of 4.6%, 20.4%, and 20.9% in physician, ER, and hospital visits.
- Mortality was higher with poor adherence: in 15,984 UK patients, poor adherence and missed visits were each associated with a 1.6-fold increase in all-cause mortality (P<0.001); another study reported an odds ratio of 1.8 (P<0.001).
- Economic impact was substantial: improved adherence was projected to reduce hospitalization/ER risk by 13%, worsening adherence to raise it by 15%, and one analysis estimated annual savings of $4.7 billion with improved adherence and $3.6 billion with reduced poor adherence.
## Methods
- Narrative review of the literature on medication adherence in T2D, focusing on the scope of the problem, consequences, key contributors, interventions, and future developments.
- The paper synthesizes findings from retrospective/observational claim-database studies, surveys, and meta-analyses; it cites examples including analyses of 238,000 MarketScan patients, >11,000 veterans, 1,198 survey respondents, and other large database studies.
- Main analysis is qualitative synthesis of reported adherence rates, outcomes, and modifiable contributors, with attention to common adherence metrics such as medication possession ratio (MPR) ≥80% and persistence definitions.
## Limitations
- The paper states that much of the evidence comes from retrospective or observational claim-database studies using widely varying definitions, making findings difficult to interpret.
- It states that intervention evidence is limited because adherence measures vary widely, hard outcomes are often lacking, interventions are not clearly explained, and follow-up is often inadequate.
- Evident from the text: this is a review, not a new primary study, so its conclusions depend on the quality and comparability of the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 1 Not valid · 57 Not checked · 17 Own results and interpretations
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In one study that tracked new prescriptions written electronically over a 12-month period for >75,000 patients, 31.4% of new prescriptions for diabetes drugs were never filled.25”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Scope of the problem
What the sources say
- Not matchedcites [25]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainn = 75,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia)”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
49 more claims
Create a free account to see all 75 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple factors contribute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication ef fi cacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2DM who discontinue or do not properly adhere to their therapy, there is an increased risk of microvascular and macrovascular complications [7], which can in turn increase healthcare costs further [5, 6].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from this survey highlight patient perspectives on reasons for treatment discontinuation among people with T2DM in the USA and UK and provide focal points for communication for these individuals when they are initiating new therapies [5].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the NICE guidance (NG28) and gastrointestinal tolerability are likely important drivers, early GLP‐1RA discontinuation is plausibly multifactorial and may also reflect perceived treatment effectiveness, complex dosing schedules, injection‐related barriers, limited access to diabetes education, economic constraints, and medication shortages. 19 , 32 , 33 , 34”
From Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Up to 50% of people with T2DM discontinue treatment by 1 year [5].”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945 · cited 2×
“65 A key element is the need for greater consistency when measuring medication adherence, which require better instruments and tools for assessment.”
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70021-0 · Cited by 1,195
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837 · cited 1×
“Even worse, it has been well documented that this cost burden has been inexorably growing worldwide.(10) A key contributor to the remarkably high rates of morbidity and mortality is chronic poor metabolic control, especially poor glycemic control.”
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726 · cited 1×
“41 In their comprehensive review of 76 studies, Claxton et al 42 found that the prescribed number of doses per day was inversely associated with medication adherence; indeed, the mean adherence across studies decreased progressively from 79% with a once-daily dose to 51% with a four times daily…”
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationPrimary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions
Fischer, M. A., Stedman, M. R., Lii, J., Vogeli, C., Shrank, W. H., Brookhart, M. A., & Weissman, J. S. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1253-9 · Cited by 572 · cited 1×
“25 This problem, often referred to as primary nonadherence, may be particularly relevant among patients who are refusing to initiate insulin or other injectable hypoglycemic therapy, typically due to injection phobia, inconvenience, poor patient–physician communication, and/or negative patient…”
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Self-citationPsychological Insulin Resistance in Patients With Type 2 Diabetes
Polonsky, W. H., Fisher, L., Guzman, S., Villa-Caballero, L., & Edelman, S. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2543 · Cited by 551 · cited 1×
“57,58 6.”
Self-citationTrends in Prevalence and Control of Diabetes in the United States, 1988–1994 and 1999–2010
Selvin, E., Parrinello, C. M., Sacks, D. B., & Coresh, J. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2411 · Cited by 532
Cramer, J. A., Benedict, Á., Muszbek, N., Keskinaslan, A., & Khan, Z. M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01630.x · Cited by 487 · cited 1×
“17 An analysis of 238,000 patients with T2D from the MarketScan data-base reported adherence rates (MPR 80”
Medication Adherence Leads To Lower Health Care Use And Costs Despite Increased Drug Spending
Roebuck, M. C., Liberman, J. N., Gemmill-Toyama, M., & Brennan, T. A. (2011) · Health Affairs · doi:10.1377/hlthaff.2009.1087 · Cited by 460 · cited 2×
“6,29 An analysis of adherence to medications used to treat diabetes, dyslipidemia, and hypertension estimated that the direct cost of poor adherence was $105.8 billion in 2010 across 230 million patients, which represented $453 per adult.”
InfluentialAdherence to diabetes medication: a systematic review
Krass, I., Schieback, P., & Dhippayom, T. (2015) · Diabetic Medicine · doi:10.1111/dme.12651 · Cited by 453 · cited 1×
“19 For the purposes of this article, we focused on one of the more common metrics and definitions of acceptable medication adherence, eg, a medication possession ratio (MPR) of 80% over the period of observation.”
Dall, T. M., Yang, W., Gillespie, K., Mocarski, M., Byrne, E., Cintina, I., Beronja, K., Semilla, A. P., Iacobucci, W., & Hogan, P. F. (2019) · Diabetes Care · doi:10.2337/dc18-1226 · Cited by 438
Dosing Frequency and Medication Adherence in Chronic Disease
Coleman, C. I., Limone, B., Sobieraj, D. M., Lee, S., Roberts, M. S., Kaur, R., & Alam, T. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.7.527 · Cited by 432 · cited 1×
“43,44 Beyond the influence of dosing schedules, recent data suggest that the overall complexity of the T2D medication regimen predicts adherence, with greater complexity contributing to poorer adherence.”
Physician-Patient Relationship and Medication Compliance: A Primary Care Investigation
Kerse, N. (2004) · The Annals of Family Medicine · doi:10.1370/afm.139 · Cited by 391 · cited 1×
“In a conceptually similar vein, Kerse et al 61 found that primary care patients’ sense of “concordance” with their physician (feeling that their needs during medical visits had been heard and addressed) predicted medication adherence over time.”
Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database
Kirkman, M. S., Rowan-Martin, M. T., Levin, R., Fonseca, V. A., Schmittdiel, J. A., Herman, W. H., & Aubert, R. E. (2015) · Diabetes Care · doi:10.2337/dc14-2098 · Cited by 388 · cited 2×
“…on large claim databases have identified key demographic factors, such as younger age, lower education level, and lower income, that are associated with poor medication adherence in T2D, 24,32 but it may be of greater importance to identify those critical factors that are potentially modifiable.”
The Role of Patient-Physician Trust in Moderating Medication Nonadherence Due to Cost Pressures
Piette, J. D., Heisler, M., Krein, S., & Kerr, E. A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1749 · Cited by 388 · cited 1×
“To highlight the potential influence of physician trust, a small study by Piette et al 63 reported that the association between medication adherence and out-of-pocket costs is minimized among those patients who report high trust in their physicians.”
Dall, T. M., Yang, W., Halder, P., Pang, B., Massoudi, M., Wintfeld, N., Semilla, A. P., Franz, J., & Hogan, P. F. (2014) · Diabetes Care · doi:10.2337/dc14-1036 · Cited by 382
(2009) · PubMed · Cited by 359
How patient cost-sharing trends affect adherence and outcomes: a literature review.
Eaddy, M. T., Cook, C. L., O'Day, K., Burch, S. P., & Cantrell, C. R. (2012) · Europe PMC (PubMed Central) · Cited by 327
for the ABC project team, Demonceau, J., Ruppar, T., Kristanto, P., Hughes, D. A., Fargher, E., Kardas, P., De Geest, S., Dobbels, F., Lewek, P., et al. (2013) · Drugs · doi:10.1007/s40265-013-0041-3 · Cited by 307
Problems Paying Out-of-Pocket Medication Costs Among Older Adults With Diabetes
Piette, J. D., Heisler, M., & Wagner, T. H. (2004) · Diabetes Care · doi:10.2337/diacare.27.2.384 · Cited by 300 · cited 1×
“32,51 To illustrate, patients with T2D receiving a low-income subsidy for Medicare Part D were found to have lower out-of-pocket costs and better medication adherence than those not receiving the subsidy.”
Predictors of adherence to diabetes medications: the role of disease and medication beliefs
Mann, D. M., Ponieman, D., Leventhal, H., & Halm, E. A. (2009) · Journal of Behavioral Medicine · doi:10.1007/s10865-009-9202-y · Cited by 288
Barriers to Insulin Initiation
Karter, A. J., Subramanian, U., Saha, C., Crosson, J. C., Parker, M. M., Swain, B. E., Moffet, H. H., & Marrero, D. G. (2010) · Diabetes Care · doi:10.2337/dc09-1184 · Cited by 254
The Impact of Treatment Noncompliance on Mortality in People With Type 2 Diabetes
Currie, C. J., Peyrot, M., Morgan, C. L., Poole, C. D., Jenkins-Jones, S., Rubin, R. R., Burton, C. M., & Evans, M. (2012) · Diabetes Care · doi:10.2337/dc11-1277 · Cited by 252 · cited 1×
“7 Similarly, Ho et al 8 reported a significant association between poor medication adherence in T2D and all-cause mortality over time (odds ratio 1.8; P 0.001).”
InfluentialCommunication and Medication Refill Adherence: The Diabetes Study of Northern California
Ratanawongsa, N., Karter, A. J., Parker, M. M., Lyles, C. R., Heisler, M., Moffet, H. H., Adler, N., Warton, E. M., & Schillinger, D. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1216 · Cited by 247
Medication Nonadherence in Diabetes
Egede, L. E., Gebregziabher, M., Dismuke, C. E., Lynch, C. P., Axon, R. N., Zhao, Y., & Mauldin, P. D. (2012) · Diabetes Care · doi:10.2337/dc12-0572 · Cited by 195
Foot, H., La Caze, A., Gujral, G., & Cottrell, N. (2016) · Patient Education and Counseling · doi:10.1016/j.pec.2015.11.004 · Cited by 185 · cited 1×
“54 In patients with T2D, such concerns about the possible negative impact of medications are associated with poor adherence 55 as well as reluctance to initiate new medications, both orals 56 as well as injectables.”
Secular Changes in the Age-Specific Prevalence of Diabetes Among U.S. Adults: 1988–2010
Cheng, Y. J., Imperatore, G., Geiss, L. S., Wang, J., Saydah, S. H., Cowie, C. C., & Gregg, E. W. (2013) · Diabetes Care · doi:10.2337/dc12-2074 · Cited by 180
Jha, A. K., Aubert, R. E., Yao, J., Teagarden, J. R., & Epstein, R. S. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1198 · Cited by 174 · cited 1×
“31 Based on this analysis, improved adherence was projected to save $4.7 billion annually, while reduced incidence of poor adherence was projected to save $3.6 billion annually.”
InfluentialBauer, A. M., Parker, M. M., Schillinger, D., Katon, W. J., Adler, N. E., Adams, A. S., Moffet, H. H., & Karter, A. J. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-014-2845-6 · Cited by 170 · cited 1×
“Physician trust: Adherence to hypoglycemic medications 59 as well as antidepressant medications 60 has been linked to patients’ trust in their physicians.”
de Vries, S. T., Keers, J. C., Visser, R., de Zeeuw, D., Haaijer-Ruskamp, F. M., Voorham, J., & Denig, P. (2014) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2013.11.003 · Cited by 168 · cited 1×
“adherence, with greater complexity contributing to poorer adherence.(45) Similarly, the convenience or complexity of medication delivery devices can influence adherence.”
Lind, M., Garcia-Rodriguez, L. A., Booth, G. L., Cea-Soriano, L., Shah, B. R., Ekeroth, G., & Lipscombe, L. L. (2013) · Diabetologia · doi:10.1007/s00125-013-3063-1 · Cited by 164
Aikens, J. E., & Piette, J. D. (2008) · Diabetes Care · doi:10.2337/dc08-1533 · Cited by 164 · cited 1×
“26,53 Numerous studies have examined the impact of this “necessity-concerns framework”; although – as noted above – while believing that one’s medications are necessary is associated with adherence, there is a consistent finding across the studies to date that patients’ concerns about their…”
Ali, M. K., Bullard, K. M., Imperatore, G., Barker, L. E., & Gregg, E. W. (2012) · PubMed · Cited by 161
Iglay, K., Cartier, S. E., Rosen, V. M., Zarotsky, V., Rajpathak, S. N., Radican, L., & Tunceli, K. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1053048 · Cited by 157 · cited 1×
“21 Another commonly used metric is medication persistence.”
Sapkota, S., Brien, J.-A. E., Greenfield, J. R., & Aslani, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118296 · Cited by 155 · cited 1×
“…of the wide variety of intervention contents revealed no single form of intervention to be consistently effective for improving adherence, 71 though multifaceted interventions were found to be more effective than single-strategy approaches, 66 and as observed in one recent review,…”
Predictors of medication adherence in patients with type 2 diabetes mellitus
Curkendall, S. M., Thomas, N., Bell, K. F., Juneau, P. L., & Weiss, A. J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.821056 · Cited by 152 · cited 8×
“In one recent meta-analysis that included randomized clinical trials of patients with T2D, persistence rates ranged from 41% to 81% and discontinuation rates ranged from 10% to 61% over a 12-month follow-up.”
InfluentialLongitudinal effects of medication nonadherence on glycemic control
Egede, L. E., Gebregziabher, M., Echols, C., & Lynch, C. P. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014526362 · Cited by 146 · cited 3×
“Among them, it is evident that poor medication adherence looms large.(16) This article reviewed the magnitude of the problem of poor medication adherence, the impact of poor adherence on long-term outcomes and health care costs, and the key contributors to poor medication adherence.”
InfluentialPatient perspectives on once‐weekly medications for diabetes
Polonsky, W. H., Fisher, L., Hessler, D., Bruhn, D. F., & Best, J. H. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01327.x · Cited by 131 · cited 1×
“57,58 6.”
Self-citationEffective interventions to improve medication adherence in Type 2 diabetes: a systematic review
Williams, J. L. S., Walker, R. J., Smalls, B. L., Campbell, J. A., & Egede, L. E. (2013) · Diabetes Management · doi:10.2217/dmt.13.62 · Cited by 116
Medication nonfulfillment rates and reasons: narrative systematic review
Gadkari, A. S., & McHorney, C. A. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903550586 · Cited by 115 · cited 1×
“34 The more firmly the patients believe that the prescribed medication is actually necessary, the more adherent they are likely to be.”
Buysman, E. K., Liu, F., Hammer, M., & Langer, J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0199-z · Cited by 101 · cited 1×
“A retrospective study of 1,321 patients with T2D treated with liraglutide (Novo Nordisk A/S, Bagsværd, Denmark) reported that 60% were persistent with therapy (no 90-day gap) over a 12-month period, but only 34% were adherent (MPR 80%).(22) Among 40,000 patients with T2D, persistence (no 30-day gap) over a 12-month…”
Clifford, S., Perez-Nieves, M., Skalicky, A. M., Reaney, M., & Coyne, K. S. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.884491 · Cited by 99 · cited 1×
“20 A review of studies found that among patients with diabetes, hypertension, and dyslipidemia, only 59% had MPR 80%.”
Breitscheidel, L., Stamenitis, S., Dippel, F. W., & Schöffski, O. (2009) · Journal of Medical Economics · doi:10.3111/13696990903479199 · Cited by 98 · cited 1×
“30 Improved medication adherence has the potential to significantly impact T2D health care costs.”
Lopez, J., Annunziata, K., Bailey, R., Morisky, D. E., & Rupnow, M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58813 · Cited by 96 · cited 1×
“37 Finally, a claims database was used to evaluate the impact of hypoglycemia-related events on costs and discontinuation rates among 212,000 patients with T2D.”
Improving diabetes medication adherence: successful, scalable interventions
Zullig, L. L., Gellad, W. F., Moaddeb, J., Crowley, M. J., Shrank, W. H., Trygstad, T. K., Liu, L., Bosworth, H. B., Granger, B. B., & Granger, C. B. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s69651 · Cited by 96
Wong, N. D., Patao, C., Wong, K., Malik, S., Franklin, S. S., & Iloeje, U. H. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113496828 · Cited by 93 · cited 1×
“5% of participants during 2009–2010.(15) A number of factors contribute to poor glycemic control, including lack of integrated care in many health care systems, clinical inertia among health care providers, and poor patient adherence to self-care recommendations.”
Antoine, S., Pieper, D., Mathes, T., & Eikermann, M. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-53 · Cited by 92 · cited 1×
“64,65 70 A closer examination of the wide variety of intervention contents revealed no single form of intervention to be consistently effective for improving adherence, 71 though multifaceted interventions were found to be more effective than single-strategy approaches, 66 and as observed in one…”
Sapkota, S., Brien, J.-A. E., Greenfield, J. R., & Aslani, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128581 · Cited by 87 · cited 1×
“…form of intervention to be consistently effective for improving adherence, 71 though multifaceted interventions were found to be more effective than single-strategy approaches, 66 and as observed in one recent review, interventions targeting medication side effects might be of particular value.”
Farr, A. M., Sheehan, J. J., Curkendall, S. M., Smith, D. M., Johnston, S. S., & Kalsekar, I. D. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0171-3 · Cited by 86 · cited 1×
“18 Similarly, a recent meta-analysis of 40 studies in which patients taking oral antidiabetic drugs found that medication adherence rates were suboptimal, with only 67.9% of patients having an MPR 80%.”
InfluentialDiBonaventura, M., Wintfeld, N., Huang, J., & Goren, A. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s55550 · Cited by 83 · cited 2×
“16,27,28 Among 11,000 veterans with T2D who were followed up for at least 5 years, poor medication adherence (MPR 80”
Ford, E. S. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00148.x · Cited by 82 · cited 1×
“Although a wide array of options are now available for treating T2D, including several new pharmacological classes of drugs that are included in the current American Diabetes Assocation/European Association for the Study of Diabetes (ADA/EASD) and American Association of Clinical Endocrinologists (AACE) recommendation…”
Bron, M., Marynchenko, M. B., Yang, H., Yu, A. P., & Wu, E. Q. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2525 · Cited by 77 · cited 1×
“38 During a 6-month interval, the risk for medication discontinuation was significantly ( P 0.0001) greater among those with a hypoglycemic event vs those with no reported hypoglycemia.”
InfluentialWalz, L., Pettersson, B., Rosenqvist, U., Deleskog, A., Journath, G., & Wändell, P. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58781 · Cited by 75 · cited 1×
“01).(36) Among T2D participants in a recent survey, 56% had experienced hypoglycemia and had higher HbA1c levels than in those with no reported hypoglycemia (Figure 3).”
The impact of treatment non-compliance on mortality in people with type 1 diabetes
Currie, C. J., Peyrot, M. F., Morgan, C. L., Poole, C., Jenkins‐Jones, S., Rubin, R. R., Burton, C. M., & Evans, M. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.10.006 · Cited by 74
Examining the Behaviour subscale of the Hypoglycaemia Fear Survey: an international study
Gonder-Frederick, L., Vajda, K., Schmidt, K. M., Cox, D. J., DeVries, J. H., Erol, Ö., Kanc, K., Schächinger, H., & Snoek, F. J. (2013) · Diabetic Medicine · doi:10.1111/dme.12129 · Cited by 71 · cited 1×
“40 The choice of medication(s) will, of course, have a major impact on the risk of hypoglycemia.”
Hajós, T. R. S., Polonsky, W. H., Pouwer, F., Gonder-Frederick, L., & Snoek, F. J. (2014) · Diabetes Care · doi:10.2337/dc13-0971 · Cited by 58 · cited 8×
“In one recent meta-analysis that included randomized clinical trials of patients with T2D, persistence rates ranged from 41% to 81% and discontinuation rates ranged from 10% to 61% over a 12-month follow-up.”
InfluentialSelf-citationLokhandwala, T., Smith, N., Sternhufvud, C., Sörstadius, E., Lee, W. C., & Mukherjee, J. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1109518 · Cited by 53
Polonsky, W. H., Fisher, L., Hessler, D., & Edelman, S. V. (2013) · Diabetic Medicine · doi:10.1111/dme.12275 · Cited by 52 · cited 1×
“In a large multinational survey, Polonsky et al 62 found that ratings of patients with T2D on the overall quality of communication with their physicians at the time of diagnosis were linked to adherence to current hypoglycemic medications.”
Self-citationBuysman, E. K., Conner, C., Aagren, M., Bouchard, J. R., & Liu, F. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.598500 · Cited by 48
Davis, S. N., Wei, W., & Garg, S. K. (2011) · Endocrine Practice · doi:10.4158/ep10401.or · Cited by 40
Grabner, M., Chu, J. W., Raparla, S., Quimbo, R. A., Zhou, S., & Conoshenti, J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2656 · Cited by 36
Zomahoun, H. T. V., de Bruin, M., Guillaumie, L., Moisan, J., Grégoire, J., Pérez, N., Vézina‐Im, L., & Guénette, L. (2015) · Value in Health · doi:10.1016/j.jval.2015.02.017 · Cited by 35
McAdam‐Marx, C., Bellows, B. K., Unni, S. K., Mukherjee, J., Wygant, G. D., Iloeje, U. H., Liberman, J. N., Ye, X., Bloom, F. J., & Brixner, D. I. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12502 · Cited by 33 · cited 1×
“35 These data may suggest that realization of patients that improvement is occurring (and that this may be due, at least to some extent, to their medications) contributes to their willingness to continue with their medications in a more reliable manner.”
Xie, L., Zhou, S., Pinsky, B. W., Buysman, E. K., & Başer, O. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0312 · Cited by 29
Perceived Treatment Efficacy: An Overlooked Opportunity in Diabetes Care
Polonsky, W. H., & Skinner, T. C. (2010) · Clinical Diabetes · doi:10.2337/diaclin.28.2.89 · Cited by 27 · cited 2×
“33”
Self-citationYala, S. M., Duru, O. K., Ettner, S. L., Turk, N., Mangione, C. M., & Brown, A. F. (2014) · BMC Health Services Research · doi:10.1186/s12913-014-0665-3 · Cited by 26 · cited 1×
“52”
Clifford, S., Perez‐Nieves, M., Skalicky, A., et al. (2013) · Value in Health · doi:10.1016/j.jval.2013.03.836 · Cited by 11
Culture change through patient engagement
Grant, B., & Colello, S. (2010) · Nursing Management · doi:10.1097/01.nurse.0000388520.46890.1d · Cited by 9
Cited by
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
“Multiple factors contribute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication efficacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63).”
BackgroundDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Lifestyle factors, self-management and patient empowerment in diabetes care
Lambrinou, E., Hansen, T. B., & Beulens, J. W. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319885455 · Cited by 261
“5% of participants achieved good glycaemic control.(12) Access to resources and support systems, patients’ attitude and expected treatment efforts, comorbidities, disease duration and risk of hypoglycaemia are the main factors that are related to inadequate glucose control.”
Background
Metadata
- Authors
- Polonsky, W., & Henry, R.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Polonsky, William
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2016-07
- Volume
- Volume 10
- Pages
- 1299-1307
- ISSN
- 1177-889X (ISSN-L)
- PMC
- PMC4966497
- OpenAlex
- W2493860075
- Cited by
- 784
- References
- 77
- Citations by year
- 2026: 93 · 2025: 97 · 2024: 89 · 2023: 82 · 2022: 108 · 2021: 106 · 2020: 106 · 2019: 54 · 2018: 34 · 2017: 13 · 2016: 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Preference and Adherence (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- medication adherence, type 2 diabetes, glycemic control, barriers to adherence, medication beliefs, medication burden, out-of-pocket costs, hypoglycemia, treatment complexity, clinical inertia, socioeconomic factors, diabetes complications, drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.